We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
HLA‐B*57:01 confers genetic susceptibility to carbamazepine‐induced SJS/TEN in Europeans.
- Authors
Mockenhaupt, Maja; Wang, Chuang‐Wei; Hung, Shuen‐Iu; Sekula, Peggy; Schmidt, Alexander H.; Pan, Ren‐You; Chen, Chun‐Bing; Dunant, Ariane; Gouvello, Sabine Le; Schumacher, Martin; Valeyrie‐Allanore, Laurence; Bellon, Teresa; Kardaun, Sylvia H.; Jan, Yun‐Shen; Chung, Wen‐Hung; Roujeau, Jean‐Claude
- Abstract
HLA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans Carbamazepine (CBZ) is a widely used antiepileptic drug for the treatment of epilepsy, as well as bipolar disorder, trigeminal neuralgia, etc Although effective for treating neurological diseases, CBZ may cause cutaneous adverse reactions ranging from mild maculopapular exanthema (MPE) to life-threatening severe cutaneous adverse reactions (SCAR), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). Furthermore, I HLA-B*57:01 i was absent in any European patient with CBZ-DRESS I HLA-B*57:01 i or I HLA-A*31:01 i was present in 55.26% (21/38) of CBZ-SCAR patients, and only in 10.96% (971/8862) of European general population controls (OR = 10.0, 95% CI = 5.3-19.1; I P i = 3.58 × 10 SP -11 sp ) (Table). Furthermore, CBZ shows affinity to HLA-B*57:01 and HLA-B*15:02 proteins only, but not HLA-B*15:01 or HLA-B*51:01 proteins (Figure B).
- Subjects
STEVENS-Johnson Syndrome; TOXIC epidermal necrolysis; SURFACE plasmon resonance
- Publication
Allergy, 2019, Vol 74, Issue 11, p2227
- ISSN
0105-4538
- Publication type
Article
- DOI
10.1111/all.13821